Lexeo Therapeutics (LXEO) Operating Leases (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Operating Leases data on file, last reported at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 26.13% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $4.5 million (down 26.13% YoY), and the FY2025 full-year result was $4.9 million, down 24.13% from the prior year.
• Operating Leases slipped to $4.5 million in Q1 2026, from $4.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $9.0 million in Q4 2022 to a low of $4.5 million in Q1 2026.
• A 5-year average of $6.6 million and a median of $6.6 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases slipped 13.49% in 2023 and dropped 26.13% in 2026, its largest moves.
• Tracing LXEO's Operating Leases over 5 years: stood at $9.0 million in 2022, then slipped by 13.49% to $7.8 million in 2023, then decreased by 17.33% to $6.4 million in 2024, then dropped by 24.13% to $4.9 million in 2025, then fell by 8.44% to $4.5 million in 2026.
• Business Quant data shows LXEO's Operating Leases at $4.5 million in Q1 2026, $4.9 million in Q4 2025, and $5.3 million in Q3 2025.